孙朔,李东海,康鹏德

• 1:四川大学华西医院关节外科

摘要(Abstract)：

糖皮质激素（glucocorticoid, GC）被广泛应用于内科疾病的治疗，但其副作用，尤其是激素诱导性骨质疏松症（glucocorticoid-induced osteoporosis, GIOP）仍是一个严重的临床问题。目前，GIOP的实际机制仍不清楚，但最新研究表明其与应激等因素导致的细胞衰老密切相关，也就是说细胞衰老可能是GIOP的一种形成机制。激素通过诱导骨组织细胞衰老，衰老细胞旁分泌衰老相关因子（senescence-associated secreted phenotype, SASP），产生细胞衰老的级联放大反应，最终形成GIOP。本文就细胞衰老与GIOP的关系、相关机制以及靶向阻断措施等方面进行综述。

关键词(KeyWords)： 糖皮质激素;细胞衰老;激素诱导性骨质疏松症

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孙朔,李东海,康鹏德

参考文献(References)：

• [1] Kalak R, Zhou H, Street J, et al. Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice[J]. Bone, 2009, 45(1):61-67.
• [2] Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis[J]. N Engl J Med, 2018, 379(26):2547-2556.
• [3] van Deursen JM. The role of senescent cells in ageing[J]. Nature,2014, 509(7501):439-446.
• [4] Khosla S, Farr JN, Tchkonia T, et al. The role of cellular senescence in ageing and endocrine disease[J]. Nat Rev Endocrinol,2020, 16(5):263-275.
• [5] Basisty N, Kale A, Jeon OH, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development[J].PLoS Biol, 2020, 18(1):e3000599.
• [6] Wang T, Yang L, Liang Z, et al. Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1axis[J].SignalTransductTargetTher,2021,6(1):143.
• [7] Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains[J]. Exp Cell Res, 1961, 25:585-621.
• [8] He S, Sharpless NE. Senescence in health and disease[J]. Cell,2017, 169(6):1000-1011.
• [9] Campisi J. Aging, cellular senescence, and cancer[J]. Annu Rev Physiol, 2013, 75:685-705.
• [10] CoppéJP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor[J]. PLoS Biol, 2008, 6(12):2853-2868.
• [11] Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence[J]. Nat Cell Biol, 2013, 15(8):978-990.
• [12] Herranz N, Gallage S, Mellone M, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype[J]. Nat Cell Biol, 2015, 17(9):1205-1217.
• [13] Laberge RM, Sun Y, Orjalo AV, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation[J]. Nat Cell Biol, 2015, 17(8):1049-1061.
• [14] Farr JN, Khosla S. Cellular senescence in bone[J]. Bone, 2019,121:121-133.
• [15] Yin Y, Chen H, Wang Y, et al. Roles of extracellular vesicles in the aging microenvironment and age-related diseases[J]. J Extracell Vesicles, 2021, 10(12):e12154.
• [16] Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo[J]. Proc Natl Acad Sci USA, 1995, 92(20):9363-9367.
• [17]于斐,雷鸣,曾晖,等.特殊染色技术在骨关节炎关节软骨形态学研究中的比较[J].中国矫形外科杂志, 2015,(19):1801-1807.
• [18] Witkiewicz AK, Knudsen KE, Dicker AP, et al. The meaning of p16(ink4a)expression in tumors:functional significance, clinical associations and future developments[J]. Cell Cycle, 2011, 10(15):2497-2503.
• [19]李兰,梁明玮,陆燕蓉,等. miR-140对早期骨关节炎软骨细胞衰老的调控作用及机制[J].中国矫形外科杂志, 2020, 28(3):252-259.
• [20] Li P, Mao WW, Zhang S, et al. Sodium hydrosulfide alleviates dexamethasone-induced cell senescence and dysfunction through targeting the miR-22/sirt1 pathway in osteoblastic MC3T3-E1cells[J]. Exp Ther Med, 2021, 21(3):238.
• [21] Valbuena Perez JV, Linnenberger R, Dembek A, et al. Altered glucocorticoid metabolism represents a feature of macroph-aging[J].Aging Cell, 2020, 19(6):e13156.
• [22]刘弼,雷鸣,肖德明.抗衰老基因SIRT1对骨关节炎的防治影响[J].中国矫形外科杂志, 2012, 20(15):1402-1404.
• [23] Casagrande S, Stier A, Monaghan P, et al. Increased glucocorticoid concentrations in early life cause mitochondrial inefficiency and short telomeres[J]. J Exp Biol, 2020, 223(Pt 15):jeb222513.
• [24] Martin LF, Richardson LS, da Silva MG, et al. Dexamethasone induces primary amnion epithelial cell senescence through telomere-P21associated pathway[J]. Biol Reprod, 2019, 100(6):1605-1616.
• [25] Wei N, Yu Y, Joshi V, et al. Glucocorticoid receptor antagonist and siRNA prevent senescence of human bone marrow mesenchymal stromal cells in vitro[J]. Cell Tissue Res, 2013, 354(2):461-470.
• [26] Wei N, Yu Y, Schmidt T, et al. Effects of glucocorticoid receptor antagonist, RU486, on the proliferative and differentiation capabilities of bone marrow mesenchymal stromal cells in ovariectomized rats[J]. J Orthop Res, 2013, 31(5):760-767.
• [27] Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis:mechanisms, management, and future perspectives[J]. Lancet Diabetes Endocrinol, 2013, 1(1):59-70.
• [28] Stewart PM, Krozowski ZS. 11 beta-hydroxysteroid dehydrogenase[J]. Vitam Horm, 1999, 57:249-324.
• [29] Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoidinduced osteoporosis and options for treatment[J]. Nat Rev Endocrinol, 2020, 16(8):437-447.
• [30] Liu X, Chai Y, Liu G, et al. Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis[J]. Nat Commun, 2021, 12(1):1832.
• [31] Li CJ, Xiao Y, Sun YC, et al. Senescent immune cells release grancalcin to promote skeletal aging[J]. Cell Metab, 2021, 33(10):1957-1973.
• [32] Kirkland JL, Tchkonia T. Clinical strategies and animal models for developing senolytic agents[J]. Exp Gerontol, 2015, 68:19-25.
• [33] Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles'heel of senescent cells:from transcriptome to senolytic drugs[J]. Aging Cell, 2015, 14(4):644-658.
• [34] Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age[J]. Nat Med, 2018, 24(8):1246-1256.
• [35] Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice[J]. Nat Med, 2017, 23(9):1072-1079.